Chinas
China’s first biosimilar Ozempic drug applies for approval
A CHINESE drugmaker has developed a biosimilar version of Novo Nordisk’s popular diabetes drug Ozempic and applied for its approval.
Hangzhou Jiuyuan Gene Engineering said on Wednesday (Apr 3) in...
China’s Zeekr renews plans to raise up to US$500 million in US IPO, sources say
ZEEKR, the premium electric vehicle (EV) brand of Chinese automaker Geely, has restarted stalled plans to raise up to US$500 million in a New York initial public offering (IPO),...
China’s Taobao working with startup on deliveries by reusable rocket
CHINESE rocket maker Space Epoch is working with Alibaba’s online shopping platform Taobao to make reusable rockets for express deliveries that could arrive globally in an hour, Space Epoch...
China’s factory activity expands for first time in six months
CHINA’S manufacturing activity expanded in March for the first time since September, a sign that the world’s second-largest economy is stabilising. The official manufacturing purchasing managers index (PMI) rose...
China’s Huawei continues rebound with strongest earnings growth since 2019
CHINA’S Huawei Technologies saw its fastest growth in four years in 2023, with a rebound in its consumer segment and income from new businesses like smart car components accelerating...
Xiaomi stakes growth on debut in China’s cut-throat EV market
XIAOMI’S US$8 billion stock rally faces a key test when the Chinese smartphone giant unveils its first electric vehicle on Thursday, as it attempts to muscle into an unfamiliar...
China’s yuan a standout funder for emerging-market carry trade
THE historic end to super-easy monetary policy in Japan and a surprise rate hike in Taiwan have strengthened the yuan’s appeal as a funding currency for the global emerging-market...
China’s Didi swings to profit in fourth quarter
DIDI Global, China’s largest ride-hailing company, on Saturday (Mar 23) reported a fourth-quarter profit, indicating that the Chinese ride-hailing leader has gradually recovered from difficulties after prolonged regulatory scrutiny....
